{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132307","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.371923+00:00","generated_at":"2026-05-20T04:54:57.943257+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neumora Therapeutics stockholders elect directors, approve option repricing and reverse split at 2025 annual meeting","bullets":["Elected Alaa Halawa (105,795,914 votes for) and Maykin Ho (114,262,481 votes for) as Class II directors.","Ratified Ernst & Young as independent auditor for fiscal 2025 with 135,734,870 votes for.","Approved repricing of certain outstanding stock options under 2020 and 2023 equity plans (101,589,422 for).","Approved reverse stock split at ratio between 1:5 and 1:30, as determined by board (134,256,461 for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132307","json":"https://secwatch.observer/filing/0001193125-25-132307.json","markdown":"https://secwatch.observer/filing/0001193125-25-132307.md","text":"https://secwatch.observer/filing/0001193125-25-132307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525132307/0001193125-25-132307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525132307/d908298d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-20T04:54:57.943257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}